NewLink, Genentech ink licensing deal for development of NLG919
The two firms have also entered into a research collaboration for the discovery of next generation IDO/TDO compounds. As part of the deal, NewLink will receive $150m in
Akeso has received approval from China’s National Medical Products Administration (NMPA) for gumokimab (AK111), an anti-Interleukin-17 (IL-17) monoclonal antibody, to treat adults with moderate-to-severe plaque psoriasis.
The DODAC recommendation is based on the safety and efficacy outcomes from ten psoriasis Phase II/III clinical trials which included nearly 4,000 patients with moderate-to-severe plaque psoriasis. Novartis
The company is focused on the development and commercialization of omega-3 fatty acid-based prescription therapeutics for the treatment of cardiovascular and metabolic conditions. MAT9001 is a prescription-only omega-3
RNS60 is a therapeutic saline containing highly potent charge-stabilized nanostructures (CSNs) that decrease inflammation and cell death. Revalesio demonstrated the ability of RNS60 to reduce the inflammatory responses
A Compassionate Use IDE allows access to an unapproved product for U.S. patients with serious or life-threatening conditions for whom the treating physician believes the treatment may provide
This license agreement combines Apricus’ expertise in men’s health with Forendo’s established leadership in SERM drug discovery, to advance the development of fispemifene as an investigational treatment for